scispace - formally typeset
K

Keith H. Newby

Researcher at Duke University

Publications -  31
Citations -  1763

Keith H. Newby is an academic researcher from Duke University. The author has contributed to research in topics: Defibrillation & Defibrillation threshold. The author has an hindex of 18, co-authored 31 publications receiving 1734 citations. Previous affiliations of Keith H. Newby include University of Wisconsin–Milwaukee & Veterans Health Administration.

Papers
More filters
Journal Article

International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina

Eric J. Topol, +424 more
- 01 Jan 1998 - 
Journal ArticleDOI

Sustained ventricular arrhythmias in patients receiving thrombolytic therapy : Incidence and outcomes

TL;DR: Sustained ventricular tachycardia (VT) and fibrillation (VF) occur in up to 20% of patients with acute myocardial infarction (MI) and have been associated with a poor prognosis as discussed by the authors.
Journal ArticleDOI

Implantable cardioverter-defibrillators and pregnancy: A safe combination?

TL;DR: Pregnancy does not increase the risk of major ICD-related complications or result in a high number of ICD discharges, and the mere presence of an ICD should not defer a women from becoming pregnant unless she has an underlying structural cardiac disease that is considered a contraindication.
Journal ArticleDOI

Incidence and Clinical Relevance of the Occurrence of Bundle-Branch Block in Patients Treated With Thrombolytic Therapy

TL;DR: Continuous 12-lead ECG monitoring provides an accurate characterization of the incidence and type of conduction disturbances after acute myocardial infarction, and thrombolytic therapy reduces the overall mortality rate associated with persistent bundle-branch block.
Journal ArticleDOI

Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial

TL;DR: Lamifiban given with thrombolytic therapy appears to be associated with more rapid and complete reperfusion than placebo and Reconciliation of ECG monitoring with clinical outcomes will require a larger, adequately powered clinical trial.